{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T21:48:10Z","timestamp":1787694490609,"version":"build-2784847793"},"reference-count":38,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,3,1]]},"abstract":"<jats:p>Objective. To examine whether treatment of premature infants with intratracheal recombinant human CuZn superoxide dismutase (r-h CuZnSOD) reduces bronchopulmonary dysplasia and improves pulmonary outcome at 1 year corrected age.<\/jats:p><jats:p>Design. Three hundred two premature infants (600\u20131200 g birth weight) treated with exogenous surfactant at birth for respiratory distress syndrome were randomized to receive either intratracheal r-h CuZnSOD (5 mg\/kg in 2 mL\/kg saline) or placebo every 48 hours (as long as intubation was required) for up to 1 month of age. Short-term, as well as longer-term pulmonary outcome was assessed.<\/jats:p><jats:p>Results. There were no differences between groups in the incidence of death or the development of bronchopulmonary dysplasia (oxygen requirement with an Edwards chest radiograph score of \u22653) at 28 days of life or 36 weeks\u2019 postmenstrual age. r-h CuZnSOD was well-tolerated and not associated with significant increases in any adverse event. At a median of 1 year corrected age, health assessments and physical examinations were performed on 209 (80%) surviving infants, with complete data available on 189 infants. Thirty-seven percent of placebo-treated infants had repeated episodes of wheezing or other respiratory illness severe enough to require treatment with asthma medications such as bronchodilators and\/or corticosteroids compared with 24% of r-h CuZnSOD-treated infants, a 36% reduction. In infants &amp;lt;27 weeks\u2019 gestation, 42% treated with placebo received asthma medications compared with 19% of r-h CuZnSOD-treated infants, a 55% decrease. Infants &amp;lt;27 weeks\u2019 gestation who received r-h CuZnSOD also had a 55% decrease in emergency department visits and a 44% decrease in subsequent hospitalizations. Growth measurements and the results of physical examinations were comparable between groups.<\/jats:p><jats:p>Conclusions. These data indicate that treatment at birth with r-h CuZnSOD may reduce early pulmonary injury, resulting in improved clinical status when measured at 1 year corrected age. r-h CuZnSOD appears to be a safe and effective therapy that improves pulmonary outcome in high-risk premature infants.<\/jats:p>","DOI":"10.1542\/peds.111.3.469","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"469-476","source":"Crossref","is-referenced-by-count":220,"title":["Pulmonary Outcome at 1 Year Corrected Age in Premature Infants Treated at Birth With Recombinant Human CuZn Superoxide Dismutase"],"prefix":"10.1542","volume":"111","author":[{"given":"Jonathan M.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pediatrics (Neonatology)"},{"name":"CardioPulmonary Research Institute, Winthrop University Hospital, SUNY Stony Brook School of Medicine, Mineola, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Parad","sequence":"additional","affiliation":[{"name":"Divisions of Newborn Medicine"},{"name":"Biostatistics, Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Michele","sequence":"additional","affiliation":[{"name":"Bio-Technology General Corporation, Iselin, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Allred","sequence":"additional","affiliation":[{"name":"Biostatistics, Children\u2019s Hospital"},{"name":"Harvard Medical School and Harvard School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Price","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Rosenfeld","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (Neonatology)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the North American Recombinant Human CuZnSOD Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,3,1]]},"reference":[{"key":"2021120919030606200_R1","doi-asserted-by":"crossref","unstructured":"Jobe A, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med.2001;163:1723\u20131729","DOI":"10.1164\/ajrccm.163.7.2011060"},{"key":"2021120919030606200_R2","doi-asserted-by":"crossref","unstructured":"Northway WH Jr. Historical perspective. Early observations and subsequent evolution of bronchopulmonary dysplasia. In: Bland RD, Coalson JJ, eds. Chronic Lung Disease in Early Infancy. New York, NY: Marcel Dekker; 2000:1\u201320","DOI":"10.1201\/b14831-2"},{"key":"2021120919030606200_R3","doi-asserted-by":"crossref","unstructured":"Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics.1988;82:527\u2013532","DOI":"10.1542\/peds.82.4.527"},{"key":"2021120919030606200_R4","doi-asserted-by":"crossref","unstructured":"Jobe A. The new BPD: an arrest of lung development. Pediatr Res.1999;46:641\u2013643","DOI":"10.1203\/00006450-199912000-00007"},{"key":"2021120919030606200_R5","unstructured":"Davis JM, Rosenfeld WN. Bronchopulmonary dysplasia. In: Avery GB, Fletcher MA, MacDonald MG, eds. Neonatology. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:509\u2013532"},{"key":"2021120919030606200_R6","doi-asserted-by":"crossref","unstructured":"Frank L, Groseclose EE. Preparation for birth into an O2-rich environment: the antioxidant enzymes in the developing rabbit lung. Pediatr Res.1984;18:240\u2013244","DOI":"10.1203\/00006450-198403000-00004"},{"key":"2021120919030606200_R7","doi-asserted-by":"crossref","unstructured":"Davis JM, Rosenfeld W, Sanders R. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol.1993;74:2234\u20132241","DOI":"10.1152\/jappl.1993.74.5.2234"},{"key":"2021120919030606200_R8","unstructured":"Padmanabhan R, Gudapaty R, Liener I, Schwartz B, Hoidal J. Protection against pulmonary oxygen toxicity in rats by the intratracheal administration of liposome-encapsulated superoxide dismutase or catalase. Am J Respir Dis.1985;132:164\u2013167"},{"key":"2021120919030606200_R9","doi-asserted-by":"crossref","unstructured":"Turrens JF, Crapo JD, Freeman BA. Protection against oxygen toxicity by intravenous injection of liposome-entrapped catalase and superoxide dismutase. J Clin Invest.1984;73:87\u201395","DOI":"10.1172\/JCI111210"},{"key":"2021120919030606200_R10","doi-asserted-by":"crossref","unstructured":"Rosenfeld W, Davis JM, Parton L, et al. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics.1996;97:811\u2013817","DOI":"10.1542\/peds.97.6.811"},{"key":"2021120919030606200_R11","doi-asserted-by":"crossref","unstructured":"Davis JM, Rosenfeld W, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics.1997;100:24\u201330","DOI":"10.1542\/peds.100.1.24"},{"key":"2021120919030606200_R12","doi-asserted-by":"crossref","unstructured":"Langenback EG, Davis JM, Robbins C, Sahgal N, Perry RJ, Simon SR. Improved pulmonary distribution of recombinant human Cu\/Zn superoxide dismutase, using a modified ultrasonic nebulizer. Pediatr Pulmonol.1999;27:124\u2013129","DOI":"10.1002\/(SICI)1099-0496(199902)27:2<124::AID-PPUL9>3.0.CO;2-E"},{"key":"2021120919030606200_R13","doi-asserted-by":"crossref","unstructured":"Toce SS, Farrell PM, Leavitt LA, Samuels DP, Edwards DK. Clinical and roentgenographic scoring systems for assessing bronchopulmonary dysplasia. Am J Dis Child.1984;138:581\u2013585","DOI":"10.1001\/archpedi.1984.02140440065017"},{"key":"2021120919030606200_R14","doi-asserted-by":"crossref","unstructured":"Greenough A, Alexander J, Burgess S, et al. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. Arch Dis Child.2002;86:40\u201343","DOI":"10.1136\/adc.86.1.40"},{"key":"2021120919030606200_R15","doi-asserted-by":"crossref","unstructured":"Greenough A, Giffin FJ, Yuksel B. Respiratory morbidity in preschool children born prematurely. Acta Paediatr.1996;85:772\u2013777","DOI":"10.1111\/j.1651-2227.1996.tb14150.x"},{"key":"2021120919030606200_R16","doi-asserted-by":"crossref","unstructured":"Van Marter LJ, Allred EA, Pagano M, et al. Do clinical markers of barotrauma and oxygen toxicity explain interhospital variation in rates of chronic lung disease. Pediatrics.2000;105:1194\u20131201","DOI":"10.1542\/peds.105.6.1194"},{"key":"2021120919030606200_R17","doi-asserted-by":"crossref","unstructured":"Dales LG, Ury HK. An improper use of statistical significance testing in studying covariables. Int J Epidemiol.1978;7:373\u2013375","DOI":"10.1093\/ije\/7.4.373"},{"key":"2021120919030606200_R18","doi-asserted-by":"crossref","unstructured":"Stark A, Carlo W, Tyson J, et al. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. N Engl J Med.2001;344:95\u2013101","DOI":"10.1056\/NEJM200101113440203"},{"key":"2021120919030606200_R19","doi-asserted-by":"crossref","unstructured":"Murphy B, Inder T, Huppi P. Impaired cerebral cortical gray matter after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics.2001;107:217\u2013221","DOI":"10.1542\/peds.107.2.217"},{"key":"2021120919030606200_R20","doi-asserted-by":"crossref","unstructured":"Ellsbury DL, Acarregui MJ, McGuiness GA, Klein JM. Variability in the use of supplemental oxygen for bronchopulmonary dysplasia. J Pediatr.2002;140:247\u2013249","DOI":"10.1067\/mpd.2002.121933"},{"key":"2021120919030606200_R21","doi-asserted-by":"crossref","unstructured":"Palta M, Sadek M, Barnet JH, et al. Evaluation of criteria for chronic lung disease in surviving very low birth weight infants. Newborn Lung Project. J Pediatr.1998;132:57\u201363","DOI":"10.1016\/S0022-3476(98)70485-8"},{"key":"2021120919030606200_R22","unstructured":"Davis JM, Parad R. The role of oxidant injury in the pathogenesis of bronchopulmonary dysplasia. In: Haddad GG, Abman SH, Chernick V, eds. Basic Mechanisms of Pediatric Respiratory Disease. 2nd ed. Hamilton, Canada: BC Decker; 2002:505\u2013517"},{"key":"2021120919030606200_R23","doi-asserted-by":"crossref","unstructured":"Frank L, Sosenko I. Failure of premature rabbits to increase antioxidant enzymes during hyperoxic exposure: increased susceptibility to pulmonary oxygen toxicity compared with term rabbits. Pediatr Res.1991;29:292\u2013296","DOI":"10.1203\/00006450-199103000-00014"},{"key":"2021120919030606200_R24","doi-asserted-by":"crossref","unstructured":"Pitkanen OM, Hallman M, Andersson SM. Correlation of free oxygen radical-induced lipid peroxidation with outcome in very low birth weight infants. J Pediatr.1990;116:760\u2013764","DOI":"10.1016\/S0022-3476(05)82668-X"},{"key":"2021120919030606200_R25","doi-asserted-by":"crossref","unstructured":"Varsila E, Pesonen E, Andersson S. Early protein oxidation in the neonatal lung is related to the development of chronic lung disease. Acta Paediatr.1995;84:1296\u20131299","DOI":"10.1111\/j.1651-2227.1995.tb13552.x"},{"key":"2021120919030606200_R26","doi-asserted-by":"crossref","unstructured":"Banks BA, Ischiropoulos H, McClelland M, Ballard PL, Ballard RA. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics.1998;101:870\u2013874","DOI":"10.1542\/peds.101.5.870"},{"key":"2021120919030606200_R27","doi-asserted-by":"crossref","unstructured":"The STOP-ROP Multicenter Study Group. Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP): a randomized, controlled trial. I: primary outcomes. Pediatrics.2000;105:295\u2013310","DOI":"10.1542\/peds.105.2.295"},{"key":"2021120919030606200_R28","doi-asserted-by":"crossref","unstructured":"Ilizarov AM, Koo HC, Kazzaz JA, et al. Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. Am J Respir Cell Mol Biol.2001;24:436\u2013441","DOI":"10.1165\/ajrcmb.24.4.4240"},{"key":"2021120919030606200_R29","doi-asserted-by":"crossref","unstructured":"Sahgal N, Davis JM, Robbins C, et al. Localization and activity of recombinant human CuZn superoxide dismutase after intratracheal administration. Am J Physiol Lung Cell Mol Physiol.1996;271:L230\u2013L235","DOI":"10.1152\/ajplung.1996.271.2.L230"},{"key":"2021120919030606200_R30","doi-asserted-by":"crossref","unstructured":"White C, Avraham K, Shanley P, Froner Y. Transgenic mice with expression of elevated levels of copper-zinc superoxide dismutase in the lungs are resistant to pulmonary oxygen toxicity. J Clin Invest.1991;87:2162\u20132168","DOI":"10.1172\/JCI115249"},{"key":"2021120919030606200_R31","doi-asserted-by":"crossref","unstructured":"Wispe J, Warner B, Clark J, et al. Human Mn-superoxide dismutase in pulmonary epithelial cells of transgenic mice confers protection from oxygen injury. J Biol Chem.1992;267:23937\u201323941","DOI":"10.1016\/S0021-9258(18)35927-1"},{"key":"2021120919030606200_R32","doi-asserted-by":"crossref","unstructured":"Carlsson L, Jonsson J, Edlun T, Marklund S. Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc Nat Acad Sci U S A.1995;92:6264\u20136268","DOI":"10.1073\/pnas.92.14.6264"},{"key":"2021120919030606200_R33","doi-asserted-by":"crossref","unstructured":"Jankov RP, Negus A, Tanswell K. Antioxidants as therapy in the newborn: some words of caution. Pediatr Res.2001;50:681\u2013687","DOI":"10.1203\/00006450-200112000-00009"},{"key":"2021120919030606200_R34","doi-asserted-by":"crossref","unstructured":"Davis JM, Richter SE, Biswas S, et al. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase. J Perinatol.2000;20:213\u2013216","DOI":"10.1038\/sj.jp.7200363"},{"key":"2021120919030606200_R35","doi-asserted-by":"crossref","unstructured":"Krilov LR. Respiratory syncytial virus: update on infection, treatment, and prevention. Curr Infect Dis Rep.2001;3:242\u2013246","DOI":"10.1007\/s11908-001-0026-3"},{"key":"2021120919030606200_R36","doi-asserted-by":"crossref","unstructured":"Sohn AH, Garrett DO, Sinkowitz-Cochran RL, et al. Prevalence of nosocomial infections in neonatal intensive care unit patients: results from the first national point-prevalence survey. J Pediatr.2001;139:821\u2013827","DOI":"10.1067\/mpd.2001.119442"},{"key":"2021120919030606200_R37","doi-asserted-by":"crossref","unstructured":"Walti H, Nicolas-Robin A, Assous M, Polla B, Bachelet M, Davis JM. The effects of exogenous surfactant and recombinant human copper-zinc superoxide dismutase on oxygen dependent anti-microbial defenses. Biol Neonate.2002;82:96\u2013102","DOI":"10.1159\/000063095"},{"key":"2021120919030606200_R38","unstructured":"Mantell L, Romashko J, Kazzaz JA, et al. Hyperoxia causes cell injury in alveolar macrophages and reduces Pseudomonas aeruginosa clearance [abstract]. Pediatr Res.2002;51:470"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/3\/469\/1003171\/pe0303000469.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/111\/3\/469\/1003171\/pe0303000469.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:43:49Z","timestamp":1682747029000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/111\/3\/469\/79844\/Pulmonary-Outcome-at-1-Year-Corrected-Age-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2003,3,1]]},"published-print":{"date-parts":[[2003,3,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.111.3.469","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,3,1]]}}}